We feel now is a pretty good time to analyse Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) business as it appears the company may be on the cusp of a considerable accomplishment. Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The US$135m market-cap company posted a loss in its most recent financial year of US$98m and a latest trailing-twelve-month loss of US$109m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is Sangamo Therapeutics' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

According to the 4 industry analysts covering Sangamo Therapeutics, the consensus is that breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of US$16m in 2027. Therefore, the company is expected to breakeven just over a year from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 60%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Sangamo Therapeutics' growth isn’t the focus of this broad overview, though, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one aspect worth mentioning. Sangamo Therapeutics currently has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are too many aspects of Sangamo Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Sangamo Therapeutics' company page on Simply Wall St. We've also compiled a list of relevant factors you should look at:

1. Valuation: What is Sangamo Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Sangamo Therapeutics is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Sangamo Therapeutics’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.